Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.

Daniela ZackovaLukáš SemerádEdgar FaberHana KlamováLukáš StejskalPetra BělohlávkováMichal KarasEduard CmuntOlga ČernáJiřina ProcházkováPetra ČičátkováAnežka KvetkováTomas HornakIvana SkoumalováDana SrbováCyril SalekDavid BuffaJaroslava VoglováTomáš JurčekAdam FoltaIvana JežíškováHana ŽižkováKateřina Machová PolákováTomáš PapajíkPavel ŽákPavel JindraAdam SvobodníkRadka ŠtěpánováJiří Mayer

Published in: Leukemia (2024)

Keyphrases

chronic myeloid leukemia
end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
clinical trial
study protocol
randomized controlled trial
phase iii
advanced non small cell lung cancer
patient reported outcomes
cross sectional
epidermal growth factor receptor